|
- 2018
Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine TumorsDOI: 10.1007/s13139-017-0505-6 Keywords: Peptide receptor radionuclide therapy, Neuroendocrine tumors, Radiolabeled somatostatin analogues, Lu-177 Abstract: Structures and chelators of PRRT for radiolabeling based on octapeptides such as octreotide (a), octreotate (b), DOTA-TOC (c), DOTA-TATE (d), and Lu-177-DOTA-TATE (e). According to the structure of Lu-177-labeled DOTA-TATE, DOTA is a chelator for the coupling of the Lu-177 and the somatostatin analogue (e
|